-
Patent Agency Ranking
公开(公告)号：US10059667B2
公开(公告)日：2018-08-28
申请号：US15110894
申请日：2015-02-03
Applicant: MERCK SHARP & DOHME CORP. , Harry Chobanian , Duane DeMong , Yan Guo , Zhiyong Hu , Michael Miller , Barbara Pio , Christopher W. Plummer , Dong Xiao , Cangming Yang , Rui Zhang
Inventor： Harry Chobanian , Duane DeMong , Yan Guo , Zhiyong Hu , Michael Miller , Barbara Pio , Christopher W. Plummer , Dong Xiao , Cangming Yang
IPC: C07D211/42 , A61K45/06 , A61K31/366 , A61K31/397 , A61K31/40 , A61K31/44 , C07D231/20 , A61K31/4985 , C07D401/04 , C07D239/52 , C07C217/52 , C07D205/04 , C07D491/056 , C07D265/30 , C07D207/08 , C07D207/10 , C07D207/12 , C07D209/52 , C07D209/54 , C07D211/22 , C07D213/30 , C07D213/64 , C07D213/65 , C07D213/69 , C07D307/86 , C07D307/88 , C07C59/72 , C07D205/12 , C07D213/647
CPC classification number: C07D211/42 , A61K31/366 , A61K31/397 , A61K31/40 , A61K31/44 , A61K31/4985 , A61K45/06 , C07C59/72 , C07C217/52 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/10 , C07D205/04 , C07D205/12 , C07D207/08 , C07D207/10 , C07D207/12 , C07D209/52 , C07D209/54 , C07D211/22 , C07D213/30 , C07D213/64 , C07D213/647 , C07D213/65 , C07D213/69 , C07D231/20 , C07D239/52 , C07D265/30 , C07D307/86 , C07D307/88 , C07D401/04 , C07D491/056 , A61K2300/00
Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号：US20160024091A1
公开(公告)日：2016-01-28
申请号：US14774390
申请日：2014-03-10
Applicant: Alexander PASTERNAK , Fa-Xiang DING , Shuzhi DONG , Haifeng TANG , Jinlong JIANG , Cangming YANG , Dipshikha BISWAS , MERCK SHARP & DOHME CORP.
Inventor： Alexander Pasternak , Fa-Xiang Ding , Shuzhi Dong , Dipshikha Biswas , Haifeng Tang , Jinlong Jiang , Cangming Yang , Xin Gu
IPC: C07D471/10 , A61K31/444 , A61K31/506 , A61K31/435 , A61K31/5386 , A61K31/501 , C07D471/20 , A61K31/4995 , C07D498/20 , A61K45/06 , A61K31/497
CPC classification number: C07D471/10 , A61K31/24 , A61K31/401 , A61K31/403 , A61K31/405 , A61K31/407 , A61K31/41 , A61K31/417 , A61K31/4178 , A61K31/4184 , A61K31/435 , A61K31/4422 , A61K31/444 , A61K31/472 , A61K31/4965 , A61K31/497 , A61K31/4995 , A61K31/501 , A61K31/506 , A61K31/519 , A61K31/5386 , A61K31/55 , A61K31/551 , A61K31/554 , A61K31/585 , A61K31/675 , A61K45/06 , C07D471/20 , C07D498/20 , A61K2300/00
Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
Abstract translation: 本发明提供式I化合物及其药学上可接受的盐，它们是ROMK（Kir1.1）通道的抑制剂。 这些化合物可以用作利尿剂和/或利尿钠剂，并且用于治疗和预防包括心血管疾病如高血压，心力衰竭和慢性肾脏疾病以及与过量的盐和水保留有关的病症的医学病症。
-
公开(公告)号：US09765074B2
公开(公告)日：2017-09-19
申请号：US14774390
申请日：2014-03-10
Applicant: Merck Sharp & Dohme Corp.
Inventor： Alexander Pasternak , Fa-Xiang Ding , Shuzhi Dong , Dipshikha Biswas , Haifeng Tang , Jinlong Jiang , Cangming Yang , Xin Gu
IPC: A61K31/24 , C07D471/10 , A61K31/401 , C07D471/20 , A61K31/403 , A61K31/405 , A61K31/407 , A61K31/41 , A61K31/417 , A61K31/4178 , A61K31/4184 , A61K31/4422 , A61K31/472 , A61K31/4965 , A61K31/519 , A61K31/55 , A61K31/551 , A61K31/554 , A61K31/585 , A61K31/675 , A61K31/435 , A61K31/444 , A61K31/497 , A61K31/4995 , A61K31/501 , A61K31/506 , A61K31/5386 , A61K45/06 , C07D498/20
CPC classification number: C07D471/10 , A61K31/24 , A61K31/401 , A61K31/403 , A61K31/405 , A61K31/407 , A61K31/41 , A61K31/417 , A61K31/4178 , A61K31/4184 , A61K31/435 , A61K31/4422 , A61K31/444 , A61K31/472 , A61K31/4965 , A61K31/497 , A61K31/4995 , A61K31/501 , A61K31/506 , A61K31/519 , A61K31/5386 , A61K31/55 , A61K31/551 , A61K31/554 , A61K31/585 , A61K31/675 , A61K45/06 , C07D471/20 , C07D498/20 , A61K2300/00
Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
-
公开(公告)号：US20160280626A1
公开(公告)日：2016-09-29
申请号：US15034189
申请日：2014-12-01
Applicant: Merck Sharp & Dohme Corp.
Inventor： Thomas Bara , Harry R. Chobanian , Yan Guo , Hubert Josien , Michael Miller , Barbara Pio , Christopher W. Plummer , Cangming Yang , Dong Xiao
IPC: C07C59/72 , C07D213/64 , A61K31/44 , C07D209/08 , A61K31/404 , C07D231/12 , A61K31/415 , C07D417/04 , A61K31/427 , C07D471/04 , A61K31/437 , C07D249/04 , A61K31/4192 , C07D333/24 , A61K31/381 , C07C255/59 , A61K31/277 , C07D221/04 , A61K31/435 , A61K45/06 , A61K31/192
CPC classification number: C07C59/72 , A61K31/192 , A61K31/277 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/4192 , A61K31/427 , A61K31/435 , A61K31/437 , A61K31/44 , A61K45/06 , C07C255/59 , C07C2601/02 , C07C2601/14 , C07C2602/06 , C07C2602/08 , C07D207/333 , C07D209/08 , C07D209/12 , C07D213/64 , C07D221/04 , C07D231/12 , C07D249/04 , C07D277/42 , C07D333/24 , C07D417/04 , C07D471/04 , A61K2300/00
Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号：US09957219B2
公开(公告)日：2018-05-01
申请号：US15034189
申请日：2014-12-01
Applicant: Merck Sharp & Dohme Corp.
Inventor： Thomas Bara , Harry R. Chobanian , Yan Guo , Hubert Josien , Michael Miller , Barbara Pio , Christopher W. Plummer , Cangming Yang , Dong Xiao
IPC: C07C59/72 , A61K45/06 , A61K31/192 , A61K31/404 , A61K31/435 , C07D221/04 , C07D231/12 , C07D207/333 , C07D277/42 , C07D209/12 , A61K31/277 , A61K31/381 , A61K31/415 , A61K31/4192 , A61K31/427 , A61K31/437 , A61K31/44 , C07C255/59 , C07D209/08 , C07D213/64 , C07D249/04 , C07D333/24 , C07D417/04 , C07D471/04
CPC classification number: C07C59/72 , A61K31/192 , A61K31/277 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/4192 , A61K31/427 , A61K31/435 , A61K31/437 , A61K31/44 , A61K45/06 , C07C255/59 , C07C2601/02 , C07C2601/14 , C07C2602/06 , C07C2602/08 , C07D207/333 , C07D209/08 , C07D209/12 , C07D213/64 , C07D221/04 , C07D231/12 , C07D249/04 , C07D277/42 , C07D333/24 , C07D417/04 , C07D471/04 , A61K2300/00
Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
-
-
-
Search Results
5
records
(took 0.019 seconds)
